Recommendation of the President – Vaxigrip (trivalent influenza vaccine (split virion), inactivated)
On 27 April 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 52/2026 on the inclusion of the medicinal product Vaxigrip (trivalent influenza vaccine (split virion), inactivated) in the reimbursement program for all registered indications as of the date of this decision